Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Migraine

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 19 articles:
HTML format



Single Articles


    March 2021
  1. ASHINA M, Katsarava Z, Do TP, Buse DC, et al
    Migraine: epidemiology and systems of care.
    Lancet. 2021 Mar 25. pii: S0140-6736(20)32160.
    PubMed     Abstract available


  2. ASHINA M, Buse DC, Ashina H, Pozo-Rosich P, et al
    Migraine: integrated approaches to clinical management and emerging treatments.
    Lancet. 2021 Mar 25. pii: S0140-6736(20)32342.
    PubMed     Abstract available


  3. ASHINA M, Terwindt GM, Al-Karagholi MA, de Boer I, et al
    Migraine: disease characterisation, biomarkers, and precision medicine.
    Lancet. 2021 Mar 25. pii: S0140-6736(20)32162.
    PubMed     Abstract available


    December 2020
  4. CROOP R, Lipton RB, Kudrow D, Stock DA, et al
    Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2020 Dec 15. pii: S0140-6736(20)32544.
    PubMed     Abstract available


  5. EDVINSSON L
    Oral rimegepant for migraine prevention.
    Lancet. 2020 Dec 15. pii: S0140-6736(20)32624.
    PubMed    


    July 2020
  6. FANDLER-HOFLER S, Enzinger C, Gattringer T
    Speechless from pain: migraine with prolonged aura.
    Lancet. 2020;396:e11.
    PubMed    


  7. VGONTZAS A, Renthal W
    Predicting erenumab adverse events with single-cell genomics.
    Lancet. 2020;396:95-96.
    PubMed    


    June 2020
  8. GASPARINI S, Torino C, Branca D, Ferlazzo E, et al
    Testing rimegepant for migraine-time to revise the trial design?
    Lancet. 2020;395:1901.
    PubMed    


  9. CROOP R, Goadsby PJ, Stock DA, Lipton RB, et al
    Testing rimegepant for migraine-time to revise the trial design? - Authors' reply.
    Lancet. 2020;395:1901-1902.
    PubMed    


    November 2019
  10. BARNETT R
    Migraine.
    Lancet. 2019;394:1897.
    PubMed    


    October 2019
  11. CHARLES A, Pozo-Rosich P
    Targeting calcitonin gene-related peptide: a new era in migraine therapy.
    Lancet. 2019 Oct 23. pii: S0140-6736(19)32504.
    PubMed     Abstract available


    August 2019
  12. THE LANCET
    Better evidence needed for preventing paediatric migraine.
    Lancet. 2019;394:612.
    PubMed    


  13. TESSITORE A, Russo A
    Is targeting CGRP the right pathway to prevent migraine?
    Lancet. 2019 Aug 16. pii: S0140-6736(19)31947.
    PubMed    


  14. FERRARI MD, Diener HC, Ning X, Galic M, et al
    Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
    Lancet. 2019 Aug 16. pii: S0140-6736(19)31946.
    PubMed     Abstract available


    July 2019
  15. EDVINSSON L
    Rimegepant oral disintegrating tablet for migraine.
    Lancet. 2019 Jul 12. pii: S0140-6736(19)31611.
    PubMed    


  16. CROOP R, Goadsby PJ, Stock DA, Conway CM, et al
    Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Lancet. 2019 Jul 12. pii: S0140-6736(19)31606.
    PubMed     Abstract available


    October 2018
  17. CHARLES A
    A new opportunity after migraine treatment failure?
    Lancet. 2018 Oct 22. pii: S0140-6736(18)32606.
    PubMed    


  18. REUTER U, Goadsby PJ, Lanteri-Minet M, Wen S, et al
    Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Lancet. 2018 Oct 22. pii: S0140-6736(18)32534.
    PubMed     Abstract available


    March 2018
  19. DODICK DW
    Migraine.
    Lancet. 2018 Mar 6. pii: S0140-6736(18)30478.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: